NEK7 Inhibitors Modulating NLRP3 Inflammasome
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current inhibitors fail to effectively target the NLRP3 inflammasome's modulated inflammatory response in diseases such as gout, atherosclerosis, Type 2 diabetes, and neurodegenerative diseases, as the mechanism of the NLRP3-NEK7 interaction is not well understood.
Innovation Solution
Development of NEK7 small molecule inhibitors with specific features like hinge-binding elements, flexible linkers, urea linkers, and hydrophobic back pocket groups to modulate the activity of the NLRP3 inflammasome, providing therapeutic or prophylactic agents for treating or preventing NLRP3-mediated disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current inhibitors are used to target the NLRP3 inflammasome, then the inflammation response is disturbed, but the therapeutic effect is insufficient due to poor understanding of the NLRP3-NEK7 interaction mechanism
Solution Approach 1:
The patent uses NEK7 as an intermediary target to indirectly modulate NLRP3 inflammasome activity. By developing inhibitors that specifically target NEK7 (a regulatory protein that interacts with NLRP3), the invention achieves therapeutic effects while bypassing the need for complete mechanistic understanding of the NLRP3-NEK7 interaction. The NEK7 inhibitor acts as a mediator to disrupt the pathological inflammasome activation pathway.
2Reliability
If NEK7 inhibitors are developed to directly target the NLRP3-NEK7 interaction, then therapeutic benefits are improved, but the complexity of drug design increases due to specific structural requirements
Solution Approach 1:
The patent applies local quality by designing inhibitors with specific functional regions that interact with particular domains of the NEK7 protein. The inhibitor molecules contain distinct pharmacophoric elements (hydrogen bond donors/acceptors, hydrophobic groups, charged groups) that target specific local regions of the NEK7 binding interface, allowing selective disruption of the NLRP3-NEK7 interaction while maintaining manageable design complexity.
Solution Approach 2:
The invention employs parameter changes by systematically varying molecular properties of the inhibitor compounds (such as hydrogen bonding capacity, hydrophobicity, charge distribution, and molecular size) to optimize binding affinity and selectivity for NEK7. These parameter adjustments allow fine-tuning of the inhibitor's therapeutic effect while managing the complexity of drug design through structured molecular optimization.
Data Source
AI summary
Compositions comprising at least one NEK7 protein and a NEK7 small molecule inhibitor compound comprising at least one of the following features: (i) a hinge-binding element comprising at least one hydrogen donor and at least one hydrogen acceptor, (ii) a flexible linker, (iii) a urea linker, or (iv) a hydrophobic back pocket group. Methods associated with preparation and use of such NEK7 inhibitors, pharmaceutical compositions comprising such NEK7 inhibitors and methods to prevent diseases or disorders (e.g., via modulation of NLRP3 inflammasome activity) are also provided.